Hanshang Great Health Industry Co., Ltd. and Wuhan Hanshang Group Co.,Ltd. (SHSE:600774) entered into an agreement to acquire Chengdu Dikang Pharmaceutical Co., Ltd. from Sichuan Blu-ray Development Co., Ltd. and Chengdu Landi Shared Enterprise Management Partnership (Limited Partnership) for CNY 900 million on July 28, 2020. Hanshang Great Health Industry Co., Ltd. and Wuhan Hanshang Group Co.,Ltd. will acquire 120 million shares. The transaction price of this share transfer is paid in two installments. Payment of the first transfer price within 5 working days after the delivery of the underlying shares, Wuhan Hanshang Group Co.,Ltd. and Hanshang Great Health Industry Co., Ltd. will pay the counterparty 51% of the share transfer price and payment of the second phase of the transfer price before May 31, 2021, Wuhan Hanshang Group Co.,Ltd. and Hanshang Great Health Industry Co., Ltd. will pay the remaining 49% of the equity transfer price. The transaction will be financed from its own funds, self-raised funds and a non-public issuance of A shares. For the year ending December 31, 2019, Chengdu Dikang Pharmaceutical Co., Ltd. reported total assets of CNY 1.08 billion, shareholder's equity of CNY 484.42 million, revenues of CNY 1.07 billion and net profit of CNY 135.98 million. The transaction is subject to the approval of Board of Wuhan Hanshang Group Co.,Ltd., shareholders of Wuhan Hanshang Group Co.,Ltd. and the State Administration for Market Regulation. The shareholders of Wuhan Hanshang Group approved the transaction on October 12, 2020. Wang Changqing of China Securities Co., Ltd. acted as financial advisor while Tan Sijun and Cheng Xuan of Jiayuan Law acted as legal advisors and Huang Xiaohua and Chen Gang of Union Power Certified Public Accountants Co., Ltd acted as accountants to Wuhan Hanshang Group Co.,Ltd.